2 research outputs found
The Equivalence of Two Open Therapeutic Regimens of Cimetidine in the Treatment of Acute Duodenal Ulcer Disease: A Canadian Multicentre Trial
One hundred and four patients completed a multicentre study
comparing the standard cimetidine regimen of 300 mg qid with cimetidine 600
mg bid in the treatment of acute duodenal ulcer. Both dosage regimens were
effective in alleviating symptoms. At the two- and four-week assessments a
significantly greater decrease in frequency, duration and severity of night time
pain was recorded in the 600 mg bid group (P<0.05). The healing rates were
equivalent in both treatment groups. After eight weeks of treatment, 96% of the
patients had healed in each treatment group. Cimetidine 600 mg bid may
represent a useful alternative therapeutic regimen to the standard 300 mg qid
dosage in patients with symptomatic acute duodenal ulcer disease
The Equivalence of Two Open Therapeutic Regimens of Cimetidine in the Treatment of Acute Duodenal Ulcer Disease: A Canadian Multicentre Trial
One hundred and four patients completed a multicentre study
comparing the standard cimetidine regimen of 300 mg qid with cimetidine 600
mg bid in the treatment of acute duodenal ulcer. Both dosage regimens were
effective in alleviating symptoms. At the two- and four-week assessments a
significantly greater decrease in frequency, duration and severity of night time
pain was recorded in the 600 mg bid group (P<0.05). The healing rates were
equivalent in both treatment groups. After eight weeks of treatment, 96% of the
patients had healed in each treatment group. Cimetidine 600 mg bid may
represent a useful alternative therapeutic regimen to the standard 300 mg qid
dosage in patients with symptomatic acute duodenal ulcer disease